| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.41 | 2e-15 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.34 | 2e-10 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.23 | 6e-09 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.31 | 1e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.27 | 1e-06 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.26 | 4e-06 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.18 | 6e-06 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.18 | 7e-06 |